Research progress of de novo synthesis reprogramming of fatty acids in lung cancer drug resistance
LAI Yating
CHEN Caixin
ZHAO Zhongxiang
JIN Jing
Abstract：Lung cancer is one of the most lethal and common cancers in the world.Tyrosine kinase inhibitors(TKIs)can target epidermal growth factor receptor(EGFR)to treat lung cancer,but patients often develop drug resistance after treatment.De novo metabolic reprogramming of fatty acids is considered to be an important reason for drug resistance in lung cancer.Therefore,targeting fatty acid synthesis related enzymes may provide a new direction for the development of anti drug resistance schemes in lung cancer.This article reviewed the relationship between de novo fatty acid synthesis and drug resist-ance in lung cancer,and discussed the functions and roles of important enzymes and key proteins in it,providing references for the development of new strategies and potential targeted drugs for the treatment of drug resistance in lung cancer.
Keywords：De novo synthesis of fatty acidsLipid metabolismLung cancerDrug resistanceEGFRTargeted therapy
Publication Date：2025-03-30
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：6( 265-269,274 )